Baidu
map

Int J Obstet Anesth:剖宫产中静脉注射右美托咪定及其在乳汁中的浓度

2017-11-13 王贵龙 “罂粟花”微信公众号

背景与目的:右美托咪定是具有高α2肾上腺素能受体选择性的镇静剂。本研究主要观察静脉注射右美托咪定在椎管内麻醉下进行剖宫产术中的作用及其在初乳中的浓度

背景与目的:右美托咪定是具有高α2肾上腺素能受体选择性的镇静剂。本研究主要观察静脉注射右美托咪定在椎管内麻醉下进行剖宫产术中的作用及其在初乳中的浓度

方  法:本研究纳入了27名于硬联合麻醉下行剖宫产的产妇。分娩及断脐后,静脉持续注射右美托咪定(6μg/ kg / h )10分钟,然后剂量调整为0.7μg/ kg / h,直到关腹完毕。于注射右美托咪定后6h、12h、24h记录产妇镇静评分、生命体征及副作用,并收集产妇的血液及初乳样品,使用液相质谱分析仪分析样品。

结  果:初乳样品来自10名产妇,产后0h产妇血浆右美托咪定平均浓度为333(303~534)pg/ml,产后6h为12.3(8.1~20.1)pg/ml,24h内右美托咪定代谢完全。6h乳汁-血浆比为0.76(0.57~0.86),婴儿的相对剂量为0.034%(0.020~0.062%)。右美托咪定停止使用时,镇静评分为-2分(-4~-1分)。术中产妇未出现恶心、腹膜刺激征及分娩后疼痛等情况。

结  论:所有产妇右美托咪定乳汁-血浆比均小于1,婴儿相对剂量非常低,所以剖宫产中使用右美托咪定镇静对婴儿不太可能造成危害。

原始出处:

Yoshimura M,et al.,Intravenous dexmedetomidine for cesarean delivery and its concentration in colostrum.Int J Obstet Anesth. 2017 Nov;32:28-32.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050908, encodeId=a8fc2050908bd, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jul 24 19:25:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011353, encodeId=bafd2011353ca, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 16 00:25:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697572, encodeId=f657169e57288, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun May 20 19:25:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492468, encodeId=c4841492468e1, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544486, encodeId=4c411544486c5, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050908, encodeId=a8fc2050908bd, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jul 24 19:25:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011353, encodeId=bafd2011353ca, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 16 00:25:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697572, encodeId=f657169e57288, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun May 20 19:25:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492468, encodeId=c4841492468e1, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544486, encodeId=4c411544486c5, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2017-12-16 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050908, encodeId=a8fc2050908bd, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jul 24 19:25:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011353, encodeId=bafd2011353ca, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 16 00:25:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697572, encodeId=f657169e57288, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun May 20 19:25:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492468, encodeId=c4841492468e1, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544486, encodeId=4c411544486c5, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
    2018-05-20 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050908, encodeId=a8fc2050908bd, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jul 24 19:25:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011353, encodeId=bafd2011353ca, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 16 00:25:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697572, encodeId=f657169e57288, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun May 20 19:25:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492468, encodeId=c4841492468e1, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544486, encodeId=4c411544486c5, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050908, encodeId=a8fc2050908bd, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Jul 24 19:25:00 CST 2018, time=2018-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011353, encodeId=bafd2011353ca, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 16 00:25:00 CST 2017, time=2017-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697572, encodeId=f657169e57288, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Sun May 20 19:25:00 CST 2018, time=2018-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492468, encodeId=c4841492468e1, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544486, encodeId=4c411544486c5, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Wed Nov 15 03:25:00 CST 2017, time=2017-11-15, status=1, ipAttribution=)]

相关资讯

Yonsei Med J:小儿整形外科术中辅助应用右美托咪定的镇痛的效果优于芬太尼

阿片类药物通常用作局部麻醉剂的硬膜外佐剂,但与潜在的严重副作用(如呼吸抑制)的发生相关。本研究旨在对比右美托咪定与芬太尼作为罗哌卡因硬膜外阻滞在小儿骨科手术中的有效性和安全性。 研究共纳入了60名择期性手术的儿童患者(3 - 12岁),采用患者自控镇痛(PCA)。手术结束前30分钟患者经硬膜外导管接受0.2%罗哌卡因(0.2毫升/公斤)以及右美托咪定(1µg/kg)或芬太尼(1µg/kg)。

JAMA Surg:术中注射右美托咪定不会改善老年患者术后谵妄的发病率

术中注射右美托咪定不会改善老年患者术后谵妄的发病率

JAMA:长期机械通气镇静:右美托咪定优于咪达唑仑和丙泊酚

重症监护病房(ICU)的患者长期使用咪达唑仑或丙泊酚镇静会对患者产生严重的不良影响。右美托咪定是一种ICU镇静常用的α-2激动剂,可缩短机械通气时间,提高病人的舒适度。

BMC Anesthesiol:右美托咪定或可有效治疗脑缺血损伤

本研究旨在探讨在PC12细胞和原代神经元细胞中右美托咪定(DMED)对缺氧缺糖(OGD)所诱导的脑损伤。研究人员将PC12细胞暴露于OGD以建立缺血模型。使用细胞存活率、凋亡相关蛋白的表达和凋亡来评估OGD诱导的细胞损伤。OGD和DMED治疗后探究氧化应激和神经营养因子的表达。OGD和DMED治疗后探究可能涉及的信号通路,并随后加入抑制剂抑制通路。最后,根据炎症因子和氧化应激的变化研究DMED对初

JAMA:右美托咪定不能改善脓毒症通气患者的临床结局

需要机械通气的脓毒症患者中,使用右美托咪定的患者并显着改善患者的死亡率或呼吸机使用天数

JAMA:机械通气的败血症患者:右美托咪定镇静是否有生存获益?

右美托咪定可为进行机械通气患者提供镇静作用,但其对败血症患者结局有何影响呢?2017年3月,发表在《JAMA》的一项研究显示,在需要机械通气的患者中,同未使用右美托咪定相比,使用右美托咪定不会显着改善死亡率或无呼吸机天数。重要性:右美托咪定可为经历机械通气患者提供镇静作用;但是,其对败血症患者的死亡率和无呼吸机天数的影响尚未被很好地研究。目的:考察右美托咪定的镇静策略是否能改善进行机械通气的败血症

Baidu
map
Baidu
map
Baidu
map